These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 14526769)

  • 1. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Kaufman JL
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526769
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture.
    Wade WE; Chisholm MA
    Am J Orthop (Belle Mead NJ); 2000 May; 29(5):397-9. PubMed ID: 10868442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Hull JH; Hull PJ
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526768
    [No Abstract]   [Full Text] [Related]  

  • 4. Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?
    Prescrire Int; 2000 Feb; 9(45):197-8. PubMed ID: 11503794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Nader F
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14526767
    [No Abstract]   [Full Text] [Related]  

  • 6. [Economic analysis of dalteparin use in knee surgery at Instituto Mexicano del Seguro Social].
    Arreola-Ornelas H; Rosado-Buzzo A; García-Mollinedo L; Dorantes Aguilar J; Muciño-Ortega E; Mould-Quevedo JF
    Cir Cir; 2012; 80(5):411-8. PubMed ID: 23351443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer-associated thrombosis: focus on extended therapy with dalteparin.
    Bick RL
    J Support Oncol; 2006 Mar; 4(3):115-20. PubMed ID: 16553136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis.
    Dranitsaris G; Vincent M; Crowther M
    Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
    Blot E; Gutman F; Thannberger A
    N Engl J Med; 2003 Oct; 349(14):1385-7; author reply 1385-7. PubMed ID: 14523150
    [No Abstract]   [Full Text] [Related]  

  • 10. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
    Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
    Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic interchange of low-molecular-weight heparins.
    Burnakis TG
    Am J Health Syst Pharm; 2000 Oct; 57(19):1797-8; author reply 1800-2. PubMed ID: 11030034
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic interchange of low-molecular-weight heparins.
    Gonzalez LS
    Am J Health Syst Pharm; 2000 Oct; 57(19):1798, 1800; author reply 1800-2. PubMed ID: 11030035
    [No Abstract]   [Full Text] [Related]  

  • 13. Use of low molecular weight heparin (dalteparin), once daily, for the treatment of deep vein thrombosis. A feasibility and health economic study in an outpatient setting. Swedish Venous Thrombosis Dalteparin Trial Group.
    Lindmarker P; Holmström M
    J Intern Med; 1996 Dec; 240(6):395-401. PubMed ID: 9010387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of dalteparin versus unfractionated heparin as venous thromboembolism prophylaxis in malignant gynecologic surgery.
    Wade WE; Spruill WJ
    Am J Ther; 2008; 15(6):512-5. PubMed ID: 19127133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investment in prolonged thromboprophylaxis with dalteparin improves clinical outcomes after hip replacement.
    Dahl OE; Pleil AM
    J Thromb Haemost; 2003 May; 1(5):896-906. PubMed ID: 12871354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
    Nishioka J; Goodin S
    J Oncol Pharm Pract; 2007 Jun; 13(2):85-97. PubMed ID: 17873108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
    Rabbat CG; Cook DJ; Crowther MA; McDonald E; Clarke F; Meade MO; Lee KA; Cook RJ
    J Crit Care; 2005 Dec; 20(4):357-63. PubMed ID: 16310608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
    Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN
    J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of edoxaban versus dalteparin for the treatment of cancer-associated thrombosis.
    Connell NT; Connors JM
    J Thromb Thrombolysis; 2019 Oct; 48(3):382-386. PubMed ID: 31228036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dalteparin vs warfarin in hip arthroplasty patients.
    Bajjoka AE
    Arch Intern Med; 2001 Mar; 161(5):776-8. PubMed ID: 11231726
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.